{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06155500",
            "orgStudyIdInfo": {
                "id": "CADPT03A12001"
            },
            "organization": {
                "fullName": "Novartis",
                "class": "INDUSTRY"
            },
            "briefTitle": "Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)",
            "officialTitle": "Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "long-term-follow-up-ltfu-of-patients-treated-with-genome-edited-autologous-hematopoietic-stem-and-progenitor-cells-hspc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2039-01-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2039-01-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-24",
            "studyFirstSubmitQcDate": "2023-11-24",
            "studyFirstPostDateStruct": {
                "date": "2023-12-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Novartis Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.",
            "detailedDescription": "This study is monitoring patients treated with OTQ923, an investigational drug product of ex vivo genome-edited autologous hematopoietic stem and progenitor cells (HSPCs) that induces fetal hemoglobin (HbF) production, for a total of 15 years following infusion to monitor long-term safety and efficacy."
        },
        "conditionsModule": {
            "conditions": [
                "Sickle Cell Disease"
            ],
            "keywords": [
                "Gene therapy",
                "genome-edited hematopoietic stem and progenitor cellular therapy",
                "sickle cell",
                "autologous transplant",
                "BCL11A"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 5,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "OTQ923",
                    "description": "Patients were administered OTQ923 while enrolled on the treatment protocol (CADPT03A12101). Enrolled patients on this study will not be administered any study treatment.",
                    "interventionNames": [
                        "Other: OTQ923"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "OTQ923",
                    "description": "There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)",
                    "armGroupLabels": [
                        "OTQ923"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with delayed adverse events that are suspected to be related to previous OTQ923 therapy",
                    "description": "Number of participants with delayed adverse events including new secondary malignancies, new incidence or exacerbation of a prior autoimmune disorder, new incidence or exacerbation of a prior rheumatologic disorder, new hematologic disorder, and other adverse events considered to be related to OTQ923 therapy.",
                    "timeFrame": "Up to 15 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Persistence of fetal hemoglobin expression",
                    "description": "Assessment of fetal hemoglobin (HbF) expression persistence in peripheral blood will be done by assessing hemoglobin fractionation",
                    "timeFrame": "Up to 15 years"
                },
                {
                    "measure": "WBC chimerism in peripheral blood",
                    "description": "Concern for loss of engraftment by monitoring the WBC chimerism annually. Modified white blood cells (WBCs) measured by droplet digital PCR (ddPCR) and NGS will be performed annually through year 5 with subsequent samples stored and run annually in the event of concern for loss of engraftment",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Accepted invitation to join based on prior treatment with gene therapy.\n2. Patients must provide informed consent prior to their entry into this study.\n\nExclusion Criteria:\n\n1. Completion of less than 1 year of safety follow-up in the treatment protocol (CADPT03A12101)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Target population includes all patients who have received OTQ923 within the treatment protocol (CADPT03A12101) and have been monitored for at least 1 year post-infusion.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "1-888-669-6682",
                    "email": "novartis.email@novartis.com"
                },
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "affiliation": "Novartis Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "St Jude Childrens Rsrch Hospital",
                    "status": "RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105-3678",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melissa Parrish",
                            "role": "CONTACT",
                            "email": "Melissa.Parrish@STJUDE.ORG"
                        },
                        {
                            "name": "Akshay Sharma",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000755",
                    "term": "Anemia, Sickle Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}